Predicting glioblastoma response to bevacizumab through marker profiling?
Bevacizumab is a humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF). It has been approved for antiangiogenic treatment
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
[2016]
|
| In: |
Neuro-Oncology
Year: 2016, Jahrgang: 18, Heft: 2, Pages: 149-150 |
| ISSN: | 1523-5866 |
| DOI: | 10.1093/neuonc/nov320 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/neuonc/nov320 Verlag, lizenzpflichtig, Volltext: https://academic.oup.com/neuro-oncology/article/18/2/149/2509286 
|
| Verfasserangaben: | Tobias Kessler (Neurology Clinic, University Hospital Heidelberg and CCU Neurooncology, German Cancer Research Center, Heidelberg, Germany) |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1697821790 | ||
| 003 | DE-627 | ||
| 005 | 20220818081024.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200511s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/neuonc/nov320 |2 doi | |
| 035 | |a (DE-627)1697821790 | ||
| 035 | |a (DE-599)KXP1697821790 | ||
| 035 | |a (OCoLC)1341319461 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Keßler, Tobias |d 1987- |e VerfasserIn |0 (DE-588)1104151693 |0 (DE-627)86164591X |0 (DE-576)470840277 |4 aut | |
| 245 | 1 | 0 | |a Predicting glioblastoma response to bevacizumab through marker profiling? |c Tobias Kessler (Neurology Clinic, University Hospital Heidelberg and CCU Neurooncology, German Cancer Research Center, Heidelberg, Germany) |
| 264 | 1 | |c [2016] | |
| 300 | |a 2 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 11.05.2020 | ||
| 520 | |a Bevacizumab is a humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF). It has been approved for antiangiogenic treatment | ||
| 773 | 0 | 8 | |i Enthalten in |t Neuro-Oncology |d Oxford : Oxford Univ. Press, 1999 |g 18(2016), 2, Seite 149-150 |h Online-Ressource |w (DE-627)357167341 |w (DE-600)2094060-9 |w (DE-576)318041839 |x 1523-5866 |7 nnas |a Predicting glioblastoma response to bevacizumab through marker profiling? |
| 773 | 1 | 8 | |g volume:18 |g year:2016 |g number:2 |g pages:149-150 |g extent:2 |a Predicting glioblastoma response to bevacizumab through marker profiling? |
| 856 | 4 | 0 | |u https://doi.org/10.1093/neuonc/nov320 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://academic.oup.com/neuro-oncology/article/18/2/149/2509286 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200511 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 1104151693 |a Keßler, Tobias |m 1104151693:Keßler, Tobias |d 910000 |d 911100 |e 910000PK1104151693 |e 911100PK1104151693 |k 0/910000/ |k 1/910000/911100/ |p 1 |x j |y j | ||
| 999 | |a KXP-PPN1697821790 |e 3664437985 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1697821790","physDesc":[{"extent":"2 S."}],"name":{"displayForm":["Tobias Kessler (Neurology Clinic, University Hospital Heidelberg and CCU Neurooncology, German Cancer Research Center, Heidelberg, Germany)"]},"id":{"eki":["1697821790"],"doi":["10.1093/neuonc/nov320"]},"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"pubHistory":["1.1999 -"],"recId":"357167341","id":{"zdb":["2094060-9"],"eki":["357167341"],"issn":["1523-5866"]},"disp":"Predicting glioblastoma response to bevacizumab through marker profiling?Neuro-Oncology","origin":[{"publisher":"Oxford Univ. Press ; Duke University Medical Center","dateIssuedKey":"1999","dateIssuedDisp":"1999-","publisherPlace":"Oxford ; Durham, NC"}],"note":["Gesehen am 21.07.23"],"type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title":"Neuro-Oncology","title_sort":"Neuro-Oncology","subtitle":"official journal of the World Federation of Neuro-Oncology"}],"part":{"text":"18(2016), 2, Seite 149-150","pages":"149-150","year":"2016","volume":"18","extent":"2","issue":"2"},"language":["eng"]}],"person":[{"family":"Keßler","display":"Keßler, Tobias","given":"Tobias","role":"aut"}],"language":["eng"],"origin":[{"dateIssuedDisp":"[2016]","dateIssuedKey":"2016"}],"note":["Gesehen am 11.05.2020"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"Predicting glioblastoma response to bevacizumab through marker profiling?","title_sort":"Predicting glioblastoma response to bevacizumab through marker profiling?"}]} | ||
| SRT | |a KESSLERTOBPREDICTING2016 | ||